1. Home
  2. CVBF vs ACAD Comparison

CVBF vs ACAD Comparison

Compare CVBF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVB Financial Corporation

CVBF

CVB Financial Corporation

HOLD

Current Price

$22.66

Market Cap

4.0B

Sector

Finance

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$24.84

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVBF
ACAD
Founded
1974
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.3B
IPO Year
2009
2000

Fundamental Metrics

Financial Performance
Metric
CVBF
ACAD
Price
$22.66
$24.84
Analyst Decision
Buy
Buy
Analyst Count
3
22
Target Price
$24.50
$30.55
AVG Volume (30 Days)
1.6M
1.7M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
3.95%
N/A
EPS Growth
5.56
69.12
EPS
0.38
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$21.47
$18.80
Revenue Next Year
$15.21
$11.70
P/E Ratio
$58.84
$1,241.50
Revenue Growth
N/A
40.45
52 Week Low
$17.95
$19.69
52 Week High
$23.37
$28.35

Technical Indicators

Market Signals
Indicator
CVBF
ACAD
Relative Strength Index (RSI) 55.84 51.72
Support Level $22.01 $20.56
Resistance Level $23.35 $25.36
Average True Range (ATR) 0.45 0.76
MACD -0.10 -0.26
Stochastic Oscillator 53.50 23.84

Price Performance

Historical Comparison
CVBF
ACAD

About CVBF CVB Financial Corporation

CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: